Dominguez G C, Costa R S, Dantas M, Kimachi T, Coimbra T M
Departamento de Clínica Médica, Faculdade de Medicine de Ribeirão Preto, Universidade de São Paulo, Brasil.
Braz J Med Biol Res. 1995 Oct;28(10):1061-4.
Several lines of experimental evidence have shown that transforming growth factor beta (TGF beta) may play major role in glomerular diseases, mediating the inflammatory response through glomerulosclerosis. In the present study we evaluated TGF beta activity in occasional urine samples from 7 normal individuals and from 15 patients (10 with focal glomerular sclerosis and 5 with membranous glomerulonephritis) using a CCL-64 mink lung cell growth inhibition assay. Urinary TGF beta activity (reported in relation to urine creatinine concentration, Ucr, mean +/- SD) was higher in patients with focal glomerular sclerosis (mean = 17.32 +/- 15.75/10 micrograms Ucr) and patients with membranous glomerulonephritis (mean = 17.78 +/- 11.53/10 micrograms Ucr) than in normal individuals (mean = 0.8 +/- 0.44/10 micrograms Ucr). We also observed that TGF beta activity in urine from patients with focal glomerular sclerosis correlated with their plasma creatinine levels (r = 0.85), suggesting that TGF beta activity may be correlated with other indices of disease progression. Our data suggest that measurement of urinary TGF beta activity could be a useful noninvasive procedure for the evaluation of renal TGF beta production, which may be useful to assess prognosis and to evaluate therapeutic efficacy in patients with renal disease.
多项实验证据表明,转化生长因子β(TGF-β)可能在肾小球疾病中起主要作用,通过肾小球硬化介导炎症反应。在本研究中,我们使用CCL-64貂肺细胞生长抑制试验,评估了7名正常个体以及15名患者(10例局灶性肾小球硬化和5例膜性肾小球肾炎)随机尿液样本中的TGF-β活性。局灶性肾小球硬化患者(平均值 = 17.32 +/- 15.75/10微克Ucr)和膜性肾小球肾炎患者(平均值 = 17.78 +/- 11.53/10微克Ucr)的尿TGF-β活性(以尿肌酐浓度Ucr表示,平均值 +/- 标准差)高于正常个体(平均值 = 0.8 +/- 0.44/10微克Ucr)。我们还观察到,局灶性肾小球硬化患者尿液中的TGF-β活性与其血浆肌酐水平相关(r = 0.85),这表明TGF-β活性可能与疾病进展的其他指标相关。我们的数据表明,测量尿TGF-β活性可能是评估肾脏TGF-β产生的一种有用的非侵入性方法,这可能有助于评估肾病患者的预后和治疗效果。